Acadia Pharmaceuticals Inc
ACAD· Nasdaq
ACADAcadia Pharmaceuticals Inc
Released Feb 25, 2026, after the close
10-K filed Feb 26, 2026, 57 days after period end · 0001193125-26-072519
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023 | Q4 2022 |
|---|---|---|---|---|
| Revenue | $283.99M | $259.60M | $231.04M | $136.49M |
| Net Income | $273.57M | $143.74M | $45.80M |
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR
| -$41.73M |
| EPS Diluted | — | — | $0.28 | -$0.26 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
